![]() | |
Clinical data | |
---|---|
Trade names | Xocova |
Other names | S-217622 |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C22H17ClF3N9O2 |
Molar mass | 531.88 g·mol−1 |
3D model (JSmol) | |
| |
|
Ensitrelvir, sold under the brand name Xocova is an antiviral medication used as a treatment for COVID-19.[2][3][4][5] It was developed by Shionogi in partnership with Hokkaido University and acts as an orally active 3C-like protease inhibitor.[6][7] It is taken by mouth.[8][9][10]
The most common adverse events include transient decreases in high-density lipoprotein and increases blood triglycerides.[8]
NHK WORLD 2024
was invoked but never defined (see the help page).